Literature DB >> 11003455

Cetirizine inhibits bradykinin-induced cutaneous wheal and flare in atopic and healthy subjects.

R Fadel1, I Ramboer, N Chatterjee, J P Rihoux, M P Derde.   

Abstract

BACKGROUND: Kinins are vasoactive mediators involved in allergic reactions. When applied on the skin or in the nose, bradykinin (BK) elicits inflammation that is poorly affected by previous H1-blockade. The aim of this study was to compare the possible effect of cetirizine (an H1-antagonist) on wheal and flare responses to BK, histamine, and compound 48/80 in atopic and healthy subjects.
METHODS: In a randomized, double-blind, crossover study, eight atopic and eight healthy subjects received cetirizine (10 mg/day) or placebo for 3 days before cutaneous tests. Intradermal tests (IDT) and prick tests (PT) were performed with BK (20 nmol/ml for IDT and 20 micromol/ml for PT), histamine (100 microg/ml IDT and 100 mg/ml PT), and compound 48/80 (100 microg/ml IDT and 100 mg/ml PT) as positive controls and saline as negative control. The skin responses were monitored by measurement of wheal and flare areas.
RESULTS: BK, histamine, and 48/80 induced wheal and flare reactions in all placebo-treated subjects. Histamine elicited larger wheal and flare reactions than BK and 48/80. IDT with BK induced four- to six-fold larger wheal and flare reaction than PT. No differences in BK-induced wheal and flare were observed between atopic and healthy subjects. In atopic subjects, cetirizine induced a significant reduction of flare reactions after the BK test (80% for IDT, and 94% for PT [P<0.01]). Moreover, cetirizine reduced significantly BK-induced wheals by 70% for IDT (P<0.01) and 65% for PT (P<0.01). A similar inhibiting effect of cetirizine was also observed in healthy subjects.
CONCLUSIONS: These findings showed that the wheal and flare reactions induced by BK challenge were markedly inhibited by previous intake of cetirizine. The mechanism by which this effect is mediated cannot be established at present.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11003455     DOI: 10.1034/j.1398-9995.2000.00322.x

Source DB:  PubMed          Journal:  Allergy        ISSN: 0105-4538            Impact factor:   13.146


  3 in total

1.  The mast cell activator compound 48/80 is safe and effective when used as an adjuvant for intradermal immunization with Bacillus anthracis protective antigen.

Authors:  Afton L McGowen; Laura P Hale; Christopher P Shelburne; Soman N Abraham; Herman F Staats
Journal:  Vaccine       Date:  2009-04-14       Impact factor: 3.641

2.  Antipruritic effect of cold stimulation at the Quchi acupoint (LI11) in mice.

Authors:  Kao-Sung Tsai; Yung-Hsiang Chen; Huey-Yi Chen; Ein-Yiao Shen; Yu-Chen Lee; Jui-Lung Shen; San-Yuan Wu; Jaung-Geng Lin; Yi-Hung Chen; Wen-Chi Chen
Journal:  BMC Complement Altern Med       Date:  2014-09-19       Impact factor: 3.659

3.  Characterisation and mechanisms of bradykinin-evoked pain in man using iontophoresis.

Authors:  Kathryn J Paterson; Laura Zambreanu; David L H Bennett; Stephen B McMahon
Journal:  Pain       Date:  2013-01-11       Impact factor: 6.961

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.